Lantheus issues early results from F-18 flurpiridaz CAD trial

10/30/2013 | Business Wire

Lantheus Medical Imaging has released preliminary findings from Phase III clinical trials of F-18 flurpiridaz, a PET myocardial perfusion imaging agent for detection of heart disease. According to the results, PET MPI with F-18 flurpiridaz outperformed SPECT in terms of sensitivity and diagnostic accuracy but did not meet an endpoint associated with identifying healthy subjects.

View Full Article in:

Business Wire

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA